T. Sasaki

The comparison between UGT1A1 single heterozygous and wild-type regarding the clinical outcomes of fixed-dose irinotecan monotherapy for advanced gastric cancer: a multicenter retrospective study

Introduction Irinotecan is a key drug for advanced gastric cancer (AGC). We previously reported that patients with UGT1A1 single heterozygous (SH) had a significantly high frequency of s...

T. Miyagishima ;

A. Tanimoto ;

S. Yuki ;

T. Honda ;

Y. Komatsu ;

Y. Kobayashi ;

T. Sasaki ;

Y. Kawamoto ;

A. Ishiguro ;

K. Hatanaka ;

M. Dazai ;

H. Nakatsumi ;

Tomo Ando , MD;

H. Yoshita ;

S. Nakano ;

K. Sawada ;

T. Muranaka ;

K. Harada ;

07/01/2019

HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody

Background Although the selection of anti-EGFR antibody as first-line treatment for metastatic colorectal cancer (mCRC) patients is now decided based on primary tumor lo...

H. Okuda ;

Y. Sasaki ;

Yasuhiro Sakata ;

M. Nakamura ;

S. Yuki ;

Taisei J. Kobayashi , MD;

Y. Komatsu ;

M. Dazai ;

T. Sasaki ;

H. Nakatsumi ;

A. Sato ;

A. Ueda ;

Ayako Yoshikawa , MD;

K. Ito ;

Y. Kawamoto ;

R. Saito ;

T. Yamamura ;

M. Yagisawa ;

A. Ishiguro ;

O. Muto ;

K. Hatanaka ;

06/28/2021

VOLTAGE: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer

IntroductionChemoradiotherapy (CRT) with surgery is standard for patients (pts) with locally advanced rectal cancer (LARC), and nivolumab (nivo) is active in microsatellite instability-h...

T. Sasaki ;

Y. Nishizawa ;

N. Nakamura ;

M. Wakabayashi ;

M. Kojima ;

Takayuki Yoshino , MD, PhD;

Y. Togashi ;

H. Bando ;

A. Sato ;

Y. Tsukada ;

H. Nishikawa ;

K. Inamori ;